Today, Vumedi, the peer-to-peer learning community for physicians, announced expanded AI capabilities that make the collective clinical experience of leading specialists easier to find and use. The announcement builds on our $104 million Series B investment in the company.
Medical innovation creates new possibilities for patients every day. Realizing that potential depends on physicians having the knowledge and confidence to bring those advances into practice. That means understanding both the latest evidence and how experienced specialists apply it, including how they evaluate new therapies, sequence treatments, perform procedures and navigate complex cases.
That is the opportunity behind Oak HC/FT’s investment in Vumedi. Roman Giverts and his team have built a trusted destination where doctors learn directly from the experts and peers advancing their fields.
Physicians face a growing volume of research, new therapies and evolving treatment approaches, alongside demanding clinical schedules. Keeping up with the published evidence is a challenge in itself. Understanding what that evidence means for a particular patient adds another layer of complexity.
Some of medicine’s most valuable knowledge comes from hearing how an experienced physician approaches a difficult decision. Guidelines and publications provide essential evidence. Specialist perspectives add the practical context that helps doctors interpret and apply it.
Vumedi brings those perspectives together through more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties. Its AI tools allow physicians to ask a clinical question, find relevant expert perspectives and explore how multiple specialists approach the same problem. They can then jump directly to the time-stamped moment in the underlying video or podcast to understand the full discussion.
This connection between an answer and the clinical experience behind it is central to Vumedi’s approach. Many AI tools retrieve or summarize the published literature. Vumedi AI starts from how practicing specialists apply it, including expert-led content that is not in the literature. AI helps physicians reach relevant expertise faster while preserving the depth and context that make it valuable.
The early engagement reinforces our conviction in that approach. Since launching less than a year ago, Vumedi’s AI tools have been used by more than 150,000 NPI-verified clinicians, generating more than one million interactions. Physicians using those tools spend 3.5 times more time on the platform and watch 122% more video than non-AI users.
Across the platform, physicians logged more than 56 million minutes of learning in the past 12 months, the equivalent of 39,000 three-day medical conferences, and Vumedi added 20,000 new videos over the same period.
For us, the significance extends beyond faster information retrieval. Easier access to relevant expertise is encouraging physicians to spend more time learning, exploring the underlying content and considering the perspectives of their peers.
Vumedi also serves an important need for life sciences companies by helping physicians understand emerging treatments and how to incorporate them appropriately into care. By building a learning community that physicians choose to engage with, Vumedi gives life sciences companies a way to bring the authentic voice of the opinion leader close to the physician at the moment of a care decision. Its AI capabilities make expert perspectives more accessible when doctors have a specific question, strengthening the connection between medical innovation and everyday clinical practice.
Roman and his team have built the business around a clear understanding of how physicians learn and what earns their trust. Since our investment, they have continued to invest in talent, R&D and product development, expanding the content, capabilities and formats available to the community.
We’re proud to support Vumedi as it makes the collective experience of physicians more accessible and helps doctors bring the latest advances to their patients.
